Scientific program

Wednesday, September 4, 2019

 15:30 – 15:45 Congress Opening Hall A
Laura Esserman, USA
Bruce Mann, Australia
 15:45 – 17:30 Plenary Session 1: Neoadjuvant therapy Hall A
Chairpersons Angela DeMichele, USA
Alastair Thompson,
USA
 15:45 – 16:30
15:45
16:00
16:15
Debate: That NACT has little role for ER+ HER2- breast cancer
Yes: Ingrid A. Mayer, USA
No: Hope S. Rugo, USA
Discussion
 16:30 – 16:45 I SPY the future: Using the neoadjuvant model to optimize outcome
Laura Esserman, USA
 16:45 – 17:30
16:45
17:00
17:15
Debate: A path CR allows de-escalation of further therapies
Yes: Javier Cortes, Spain
No: Mark D. Pegram, USA
Discussion
17:30 – 19:00 Plenary Session 2: Barriers to progress Hall A
Chairpersons Bruce Mann, Australia
Richard de Boer, Australia
17:30 – 17:50 Why data does often not change opinion
Steven Goodman, USA
17:50 – 18:00 Discussion
18:00 – 18:30
18:00
18:10
18:20
Debate: That RCTs are the only way to change practice
Yes: Alistair Ring, UK
No: Donald Berry, USA
Discussion
18:30 – 18:50 Why the FDA is looking to real world evidence
18:50 – 19:00 Discussion
19:00 Networking Reception Hall A

Thursday, September 5, 2019

06:45 – 08:00 Morning Industry Symposium: 
Supported by Endomag
Breakfast will be served prior to the session
Hall B
08:00 – 09:30 Plenary Session 3: Genetics Hall A
Chairpersons Laura Esserman, USA
Ava Kwong, Hong Kong
 08:00 – 08:35
08:00
08:10
08:20
Debate: That most patients with breast cancer should be panel tested
Yes: Laura Van t’veer, USA
No: Allison W. Kurian,
USA
Discussion
08:35 – 09:10
08:35
08:45
08:55
Debate: That all gene carriers with early breast cancer should have a bilateral mastectomy
Yes: Rita Mukhtar, USA
No: Ava Kwong,
Hong Kong
Discussion
09:10 – 09:30 Interplay of lifestyle and genetics in breast cancer
Dean Ornish, USA
09:30 – 10:30 Parallel Session 4: Endocrine therapy side effects Hall A
Chairpersons Allison W. Kurian, USA
09:30 – 10:00
09:30
09:40
09:50
Debate: That topical estrogens are an acceptable treatment in patients with HR+ve early breast cancer
Yes: Michelle Melisko, USA
No: Alistair Ring,
UK
Discussion
10:00 – 10:30
10:00
10:10
10:20
Debate: How to best manage endocrine therapy symptoms: Pharma or Sweat
Sweat: Michelle Melisko, USA
Pharma: Sara A. Hurvitz,
USA
Discussion
10:30 – 11:00 Coffee break and poster viewing
09:30 – 10:30 Parallel Session 5: Imaging /Screening Hall B
Chairpersons Bruce Mann, Australia
Nola M. Hylton, USA
09:30 – 09:45 MRI screening in women without hereditary risk
Ritse Mann, The Netherlands
09:45 – 09:55 The implications of a move to MRI screening
Allison Rose, Australia
09:55 – 10:15
09:55
10:05
Debate: That women with low risk for breast cancer should only be screened every 3 years
Yes: Andrea LaCroix, USA
No:  Heather Greenwood, USA
10:15 – 10:30 Panel discussion:
Andrea LaCroix, USA
Ritse Mann, The Netherlands
Allison Rose, Australia
Heather Greenwood, USA
10:30 – 11:00 Coffee break and poster viewing
11:00 – 12:35 Parallel Session 6: HER2 positive breast cancer Hall A
Chairpersons Stacy Moulder, USA
Kevin Kalinsky, USA
11:00 – 11:35
11:00
11:10
11:20
Debate: That all high-risk adjuvant HER-2 patients should receive dual antibody therapy
Yes: Mark D. Pegram, USA
No: Antonio Llombart, Spain
Discussion
11:35 – 12:10
11:35
11:45
11:55
Debate: That shorter durations of anti HER2 therapy are now warranted in selected patients
Yes: Sara A. Hurvitz, USA
No: Javier Cortes, Spain
Discussion
12:10 – 12:30 De-escalating therapy in HER2 positive disease
Rebecca Dent, Singapore
12:30 – 14:00 Lunch break and poster viewing
11:00 – 12:30 Parallel Session 7: DCIS Hall B
Chairpersons Hiram S. Cody, USA
Donna Pinto, USA
11:00 – 11:35
11:00
11:10
11:20
Debate: That most DCIS should not be a target for screening
Yes: Laura Esserman, USA
No: Bruce Mann,
Australia
Discussion
11:35 – 12:10
11:35
11:45
11:55
Debate: Most patients with DCIS should not have radiotherapy after Breast Conserving Surgery
Yes: Alastair Thompson, USA
No: Thomas A. Buchholz, USA
Discussion
12:10 – 12:30 Role of genomic assays in DCIS
Rita Mukhtar, USA
12:30 – 14:00 Lunch break and poster viewing
 14:00 – 15:30 Plenary Session 8: Imaging in systemic disease Hall A
Chairpersons Angela DeMichele, USA
Debra Ikeda, USA
14:00 – 14:55 Imaging as a biomarker
14:00 Can we predict outcomes using imaging characteristics?
Ritse Mann, The Netherlands
14:15 Lessons from I SPY
Elissa Price, USA
14:30 What is in a sequence: Are all breast MRIs the same?
Nola M. Hylton, USA
14:45 Discussion
14:55 – 15:30
14:55
15:05
15:15
Debate: That PET CT alone should be the diagnostic tool of choice for metastatic workup for stage 2/3  patients
Yes: Robert Flavell, USA
No: Richard de Boer, Australia
Discussion
15:30 – 16:00 Coffee break and poster viewing
16:00 – 17:30 Parallel Session 9: Issues in locoregional management Hall A
Chairpersons Michael Alvarado, USA
Jiong Wu, China
16:00 – 16:35
16:00
16:10
16:20
Debate: Despite ACOSOG Z11 and AMAROS, there is still a role for axillary surgery in patients with a positive sentinel node
Yes: Abigail Caudle, USA
No: Hiram S. Cody, USA
Discussion
16:35 – 17:10
16:35
16:45
16:55
Debate: That regional nodal radiation should be routine for patients with axillary metastasis
Yes: Thomas A. Buchholz, USA
No: Catherine Park, USA
Discussion
17:10 – 17:30 Management of chronic lymphedema: Are we there yet?
Mark V. Schaverien, USA
16:00 – 17:30 Parallel Session 10: Free Papers Hall B
Chairpersons Javier Cortes, Spain
Richard Schwab, USA
16:00 – 16:10
16:10 – 16:20
16:20 – 16:30
16:30 – 16:40
16:40 – 16:50
16:50 – 17:00
17:00 – 17:10
17:10 – 17:20
17:20 – 17:30
17:30 – 18:30 Poster Session with drinks Poster area

Friday, September 6, 2019

08:00 – 09:30 Parallel Session 11: Adjuvant endocrine therapy Hall A
Chairpersons Michelle Melisko, USA
Rebecca Dent, Singapore
08:00 – 08:45
08:00
08:15
08:30
Debate: That side effects of dual endocrine therapy outweigh the benefits for most young women
Yes: Richard De Boer, Australia
No: Ingrid A. Mayer,
USA
Discussion
08:45 – 09:30
08:45
09:00
09:15
Debate: That ten years of adjuvant endocrine therapy is overtreatment for most patients
Yes: Mariana Chavez MacGregor, USA
No: Richard Schwab,
USA
Discussion
08:00 – 09:30 Parallel Session 12: Imaging as locoregional staging Hall B
Chairperson Alastair Thompson, USA
Allison Rose, Australia
08:00 – 08:35
08:00
08:10
08:20
Debate: That axillary ultrasound is an essential part of early breast cancer workup
Yes: Debra M. Ikeda, USA
No: Hiram S. Cody, USA
Discussion
08:35 – 09:15
08:35
08:45
08:55
Debate: That contrast imaging should be part of the workup of early breast cancer
Yes: Christiane Kuhl, Germany
No: Michael Alvarado, USA
Discussion
09:15 – 09:30 Intraoperative imaging
Julia Camps-Herrero, Spain
09:30 – 10:30 Parallel Session 13: Triple negative breast cancer Hall A
Chairpersons Antonio Llombart, Spain
Mariana Chavez MacGregor, USA
09:30 – 10:10
09:30
09:45
10:00
Debate: That immunotherapy will become standard of care for TN MBC
Yes: Rebecca Dent, Singapore
No: Kevin Kalinsky, USA
Discussion
10:10 – 10:30 New strategies in early TNBC
Stacy Moulder, USA
10:30 – 11:00 Coffee break and poster viewing
09:30 – 10:30 Parallel Session 14: Management of impalpable lesions Hall B
Chairpersons Judy C. Boughey, USA
Amit Agarwal, UK
09:30 – 09:40 Why we need to change
Bruce Mann, Australia
09:40 – 09:50 The case for Magtrace
Michael Alvarado, USA
09:50 – 10:00 The case for ICG
Ava Kwong, Hong Kong
10:00 – 10:10 The case for Seeds
Abigail S. Caudle, USA
10:10 – 10:20 The case for RFID (Savi-scout)
10:20 – 10:30 Discussion
10:30 – 11:00 Coffee break and poster viewing
11:00 – 12:30 Plenary Session 15: Issues in advanced disease Hall A
Chairpersons Ingrid A. Mayer, USA
Sara A. Hurvitz,
USA
11:00 – 11:35
11:00
11:10
11:20
Debate: After response of denovo metastatic breast cancer, how should the primary lesion be managed?
Wait and watch: Richard Schwab, USA
Same as for early stage disease: Judy C. Boughey, USA
Discussion
11:35 – 11:55 Oligometastatic disease should be treated with curative intent
Catherine Park, USA
11:55 – 12:30
11:55
12:05
12:15
Debate: That the ASCO guidelines for palliative care should be internationally applied
Yes: Michael W. Rabow, USA
No: Stephen Chia, Canada
Discussion
12:30 – 13:45 Lunch break and poster viewing
12:45 – 13:45 Industry Lunch Symposium:
Supported by Genentech
Hall B
13:45 – 15:15 Parallel Session 16: Reconstruction Hall A
Chairpersons Thomas A. Buchholz, USA
13:45 – 14:20
13:45
13:55
14:05
Debate: That one surgeon is better than two
Yes: Amit Agrawal, UK
No: Mark V. Schaverien, USA
Discussion
14:20 – 14:40 Prepectoral implants
Merisa Piper, USA
14:40 – 15:15
14:40
14:50
15:00
Debate: That patients requiring postmastectomy radiotherapy should not undergo immediate reconstruction
Yes: Alastair Thompson, USA
No: Jiong Wu, China
Discussion
13:45 – 15:15 Parallel Session 17: Metastatic Breast Cancer Hall B
Chairpersons Mark Pegram, USA
Alistair Ring,
UK
13:45 – 14:20
13:45
13:55
14:05
Debate: CDK 4/6 inhibitors should be first line therapy for all patients with newly diagnosed HR+ MBC
Yes: Stephen Chia, Canada
No: Mariana Chavez MacGregor, USA
Discussion
14:20 – 14:40 What is the approach for patients progressing on CDK 4/6 inhibitors?
Angela DeMichele, USA
14:40 – 15:15
14:40
14:50
15:00
Debate: ctDNA is now the best method to monitor response in patients with metastatic breast cancer
Yes: Kevin Kalinsky, USA
No: Antonio Llombart, Spain
Discussion
15:15 – 16:15 Plenary Session 18: Vision for breast cancer 2025 Hall A
Chairpersons Bruce Mann, Australia
Alastair Thompson, USA
15:15 – 15:25 Early detection
Christiane Kuhl, Germany
15:25 – 15:35 Pathology
Alexander “Sandy” D. Borowsky, USA
15:35 – 15:45 Diagnostics
Laura van t’Veer, USA
15:45 – 15:55 Locoregional treatment
Judy C. Boughey, USA
15:55 – 16:05 Systemic therapy
Angela DeMichele, USA
16:05 – 16:15 Supportive care
Michael W. Rabow, USA
16:15 – 16:30 Congress closing and award presentation Hall A
Chairpersons Bruce Mann, Australia
Alastair Thompson, USA